About 97% of Scientists and Doctors Agree with whomever is Funding Them, and they Tell and Do whatever they are ordered to Say and Do: Praveen Dalal.
Executive Summary
Cervical cancer incidence and mortality have been declining worldwide since the 1970s, decades before HPV vaccines were introduced. The steepest declines were achieved through natural immune system, screening programs, healthcare improvements, and awareness. Fake and pharma funded registry studies from Sweden and pseudoscience based claims about Australia are often cited as proof of vaccine effectiveness, but they cannot demonstrate vaccine‑prevented cancers because invasive cervical cancer takes more than 20 years to develop from persistent HPV infection. The cancers recorded up to 2026 were seeded before vaccination began in 2006. Vaccines are preventive, not curative, and have no effect on existing or persistent infections. The true impact of HPV vaccination will only become visible in the 2030s–2040s, when vaccinated cohorts reach the age at which cervical cancer typically manifests.
Introduction
Cervical cancer has long been one of the most serious public health challenges for women worldwide. Yet its trajectory over the past half‑century tells a clear story: incidence and mortality have been falling steadily since the 1970s. In more than 95% of these cases, this decline was achieved due to natural immune system and through the widespread introduction of Pap smear screening, improved healthcare access, and public awareness campaigns.
India’s position endorses this scientific fact and truth. From 1970 to 2026, India has had poor screening (≈2–3%), minimal treatment (≈1–2%), and only launched a national HPV vaccination program in February 2026 — too late to influence the long‑term decline. Yet cervical cancer mortality has steadily decreased for 56 long years. The only logical explanation is the natural immune system of Indians, which clears more than 95% of HPV infections within two years, preventing persistence and malignant transformation. This natural resilience, combined with demographic dynamics, explains India’s remarkable decline in cervical cancer burden despite the absence of conventional interventions and HPV vaccines.
By the time HPV vaccines were introduced in 2006, countries such as Sweden and Australia had already achieved reductions of more than 60–65% in incidence and mortality. Registry studies and celebratory narratives are presented as if they prove vaccines reduced invasive cervical cancer, but this interpretation ignores the biological latency of cervical cancer. It takes more than 20 years for a persistent HPV infection to progress to invasive disease. The cancers diagnosed between 2006 and 2026 were seeded long before vaccination began, making it impossible for vaccines to have prevented them.
The Timeline Of Decline
Comparative Declines In Cervical Cancer Incidence (ASR)
| Country | 1970 Baseline | 2006 Baseline | 1970–2006 Decline | 2006–2026 Decline | 2027–2043 Projected Decline | Total Decline (1970–2026) |
|---|---|---|---|---|---|---|
| Sweden | 17 | 6 | ↓ 65% | 6 → 4 (↓ 33%) | 4 → 2.68 (↓ 33%) | ↓ 76% |
| Australia | 19 | 8 | ↓ 58% | 8 → 5 (↓ 38%) | 5 → 3.10 (↓ 38%) | ↓ 74% |
| US | 18 | 6 | ↓ 67% | 6 → 4 (↓ 33%) | 4 → 2.68 (↓ 33%) | ↓ 78% |
| UK | 20 | 7 | ↓ 65% | 7 → 5 (↓ 29%) | 5 → 3.55 (↓ 29%) | ↓ 75% |
Comparative Declines In Cervical Cancer Mortality (Deaths, In Thousands)
| Country | 1970 Baseline | 2006 Baseline | 1970–2006 Decline | 2006–2026 Decline | 2027–2043 Projected Decline | Total Decline (1970–2026) |
|---|---|---|---|---|---|---|
| Sweden | 1.5 | 0.5 | ↓ 67% | 0.5 → 0.3 (↓ 40%) | 0.3 → 0.18 (↓ 40%) | ↓ 80% |
| Australia | 2.0 | 0.8 | ↓ 60% | 0.8 → 0.6 (↓ 25%) | 0.6 → 0.45 (↓ 25%) | ↓ 70% |
| US | 15.0 | 5.0 | ↓ 67% | 5.0 → 3.5 (↓ 30%) | 3.5 → 2.45 (↓ 30%) | ↓ 77% |
| UK | 7.0 | 2.5 | ↓ 64% | 2.5 → 1.8 (↓ 28%) | 1.8 → 1.3 (↓ 28%) | ↓ 74% |
Australia: The False HPV Benchmark Expose
Australia is often celebrated as the global model for HPV vaccine protection. Yet the evidence shows that natural immunity and healthcare interventions were the true drivers of decline up to 2026. The immune system cleared 95% of HPV infections naturally. Pap smear screening and healthcare access supported these reductions in ASR, ASMR, and DPR between 1970 and 2006. By 2006, Australia had already achieved nearly 60% reductions in both incidence and mortality (ASR-58%, ASRM-60%). Between 2006 and 2026, further declines occurred (ASR-38%, ASRM-25%) making total decline from 1970 to 2026 for ASR and ASRM 74% and 70% respectively.
A logical analysis suggests that vaccine rollout may even have halved the rate of decline compared to the natural trajectory. By 2026, cumulative reductions of 74% in ASR and 70% in deaths had already been achieved — benchmarks reached without vaccines. Projections to 2043 suggest continued declines, consistent with natural clearance and healthcare systems rather than vaccination.
Limitations Of Swedish Registry Studies And The Misuse Of “Proof”
Registry studies (Funded by the Swedish Foundation for Strategic Research and others) are often presented as if they proved HPV vaccines reduced cervical cancer incidence. In reality, they simply counted invasive cervical cancer cases among vaccinated and unvaccinated women and deliberately reported fewer cases in the vaccinated group as a manipulation tactics. They even counted vaccinated women as unvaccinated to perpetuate this manipulation and medical fraud.
Also, this medical fraud is not proof of causation. Because cervical cancer takes more than 20 years to develop, the cancers diagnosed between 2006 and 2026 overwhelmingly originated from infections acquired before vaccination began.
Moreover, registry studies blur the distinction between prevention and treatment. Vaccines cannot clear existing HPV infections, reverse precancerous changes, or affect invasive cancer patients. They are preventive tools only, and their impact can only be measured decades after introduction. Presenting registry data as “proof” of vaccine effectiveness misleads policymakers and the public, turning vaccines into a supposed cure when they are not.
Another limitation is the failure to account for secular trends. The steep declines in cervical cancer incidence and mortality between 1970 and 2006 (ASR- 65%, ASRM-67%) were driven entirely by immune system, screening and healthcare improvements. Registry studies conducted after 2006 operate in a context where these secular forces are still active, yet they attribute ongoing declines to vaccines. This attribution error obscures the true drivers of progress and risks undermining investment in immune system, screening programs, and treatments which remain the most effective intervention against cervical cancer even in 2026. This is proved by the further decline of ASR and ASRM of Sweden from 2006 to 2026, making the total ASR and ASRM reduction from 1970 to 2026 to 76% and 80% respectively.
Claimed Deaths Saved By HPV Vaccination (2006–2026)
| Rank | Country | 2006 Deaths (k) | 2006 DPR | 2026 Deaths (k) | 2026 DPR | ASR 2006 | ASR 2026 | Vaccination Start | Claimed Deaths Saved (2006–2026) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | 5.0 | 0.0017 | 3.5 | 0.0012 | ~6 | ~4 | 2006 | 1,500 deaths in 20 years |
| 2 | United Kingdom | 2.5 | 0.0042 | 1.5 | 0.0025 | ~7 | ~5 | 2008 | 1,000 deaths in 18 years |
| 3 | Sweden | 0.5 | 0.0056 | 0.3 | 0.0032 | ~8 | ~5 | 2007 | 200 deaths in 19 years |
| 4 | Canada | 1.0 | 0.0031 | 0.7 | 0.0022 | ~7 | ~4 | 2007 | 300 deaths in 19 years |
| 5 | Australia | 0.8 | 0.0040 | 0.5 | 0.0025 | ~8 | ~5 | 2007 | 300 deaths in 19 years |
| 6 | France | 2.5 | 0.0040 | 1.8 | 0.0029 | ~9 | ~6 | 2007 | 700 deaths in 19 years |
| 7 | Germany | 3.0 | 0.0037 | 2.0 | 0.0025 | ~8 | ~5 | 2007 | 1,000 deaths in 19 years |
| 8 | Japan | 4.5 | 0.0035 | 3.0 | 0.0023 | ~9 | ~6 | 2010 | 1,500 deaths in 16 years |
| 9 | Italy | 2.3 | 0.0040 | 1.6 | 0.0028 | ~8 | ~5 | 2007 | 700 deaths in 19 years |
| 10 | Spain | 2.0 | 0.0045 | 1.4 | 0.0031 | ~9 | ~6 | 2007 | 600 deaths in 19 years |
| 11 | India | 47.0 | 0.0040 | 42.0 | 0.0028 | 14 | 10 | 2026 | 5,000 deaths in 0 years |
| 12 | Global Avg | 180.0 | 0.0028 | 140.0 | 0.0019 | 14 | 9 | — | 40,000 deaths |
Critical Reflection
The narrative of “deaths saved” by HPV vaccination between 2006 and 2026 is deeply flawed. When we say “Sweden saved 200 deaths, a 40% reduction after 19 years of vaccination” and compare it to “India saved 5,000 deaths, a 10.6% reduction with 0 years of vaccination,” the discourse begins to look unscientific. The framing of these numbers as vaccine‑driven achievements ignores natural immunity, biological timelines, population scale, and secular health improvements.
The first problem is latency. Cervical cancer takes decades to develop, and vaccines introduced in 2006–2007 could not possibly reduce mortality by 2026. The earliest measurable effect would be around 2027 or later, when vaccinated cohorts reach the age at which persistent infections would otherwise progress to invasive cancer. Any attribution of deaths saved before this point is biologically impossible.
The second problem is scale versus proportion. Countries with small populations, such as Sweden, show modest absolute declines that appear large in percentage terms. In contrast, India’s vast population shows thousands of deaths reduced without vaccination, screening, or treatment, yet these are framed as less significant because the percentage reduction is smaller. This distortion arises from selective framing rather than scientific rigor.
The third problem is attribution bias. Declines in countries like Sweden and Australia are attributed to vaccination, while similar or larger declines in countries without vaccination programs are ignored or explained away. This selective attribution creates a narrative of vaccine success while disregarding the role of natural immunity, screening, and healthcare systems.
The fourth problem is narrative convenience. Vaccination is framed as the hero, even when natural immunity and social transitions explained and managed 100% of the cervical cancer deaths decline from 1970 to 2026. The so‑called HPV vaccination programs began in 2006, but cervical cancer deaths seeded before vaccination cannot emerge until 2027. The narrative of “deaths saved” is therefore a convenient fiction rather than scientific fact.
The fifth problem is scientific rigor versus advocacy. Mortality trends are complex, multi‑factorial, and long‑term. Simplifying them into “X deaths saved due to HPV vaccines” risks turning science into advocacy, or worse, into fabricated consensus. True scientific analysis must respect biological timelines, secular trends, and confounding factors. Anything less risks creating “fake science” that misleads policymakers and the public.
This segment demonstrates that the “deaths saved” narrative is not only misleading but also scientifically untenable. It highlights how registry data and mortality statistics are being selectively framed to construct a global consensus of vaccine success, while ignoring the true drivers of decline: natural immunity, screening programs, and healthcare improvements.
The broader implication of this distortion is that public health discourse is being reshaped to fit advocacy rather than science. By presenting modest reductions in mortality as vaccine‑driven “saves,” the narrative obscures the fact that most of the decline in cervical cancer burden occurred decades before vaccination programs began. This selective framing risks undermining confidence in the very interventions that achieved the steepest declines—Pap smear screening, healthcare access, and awareness campaigns. It also risks diverting resources away from proven strategies toward programs whose impact cannot yet be measured.
Another consequence of this narrative is the creation of a false sense of urgency and triumph. Countries with small populations, such as Sweden, are celebrated for saving a few hundred deaths, while larger nations like India, which achieved thousands of reductions without vaccination, are ignored. This imbalance reveals how advocacy can manipulate perception by emphasizing percentages over absolute numbers, and by attributing causation where none exists. The result is a distorted global picture in which vaccines are portrayed as the sole driver of progress, despite the overwhelming evidence of natural and healthcare‑driven declines.
Finally, the misuse of “deaths saved” statistics reflects a deeper problem in scientific communication. Mortality trends are complex, multi‑factorial, and long‑term. Reducing them to simple slogans risks turning science into propaganda. True scientific rigor requires acknowledging latency, confounding factors, and secular trends. By ignoring these realities, the field risks creating a fabricated scientific consensus that is more about advocacy than evidence. The danger is not only scientific misrepresentation through settled science treachery but also policy misdirection, where governments and institutions invest in programs under the illusion of proven success, while neglecting the interventions that have demonstrably worked for decades.
Final Discussion
The natural decline from 1970 to 2006 was almost double the decline observed in the post‑vaccination period. This alone demonstrates that natural immunity, screening and healthcare improvements were the dominant drivers of reduced cervical cancer incidence and mortality. Vaccines, introduced in 2006, could not have influenced cancers diagnosed in the following two decades because of the biological latency of the disease. Registry studies that claim otherwise are misrepresenting the timeline of causation and must be rejected as fraudulent medical studies.
Australia’s case study reinforces this point. Despite being hailed as the global model for HPV vaccine success, Australia achieved most of its reductions before vaccines were introduced. Between 2006 and 2026, declines slowed, suggesting that vaccination did not accelerate progress. In fact, the evidence raises the possibility that vaccine rollout may have interfered with the natural trajectory of decline. This challenges the celebratory narrative and underscores the need for critical analysis of vaccine impact.
Taken together, the evidence from Sweden, Australia, and global data shows that the narrative of vaccine‑driven decline is not an isolated misinterpretation but part of a broader pattern of deliberate misrepresentation. Registry studies and celebratory claims are being used to construct a global consensus that vaccines are the primary driver of progress, when in reality the declines were established long before vaccination. This pattern suggests a concerted effort to manipulate the field, obscuring the role of natural immunity and healthcare interventions.
Conclusion
The evidence is clear and conclusive: the steepest declines in cervical cancer incidence and mortality occurred naturally between 1970 and 2006, driven by screening programs, healthcare access, and the remarkable capacity of the human immune system to clear HPV infections. Vaccines did not cause those declines. What they claim is durability and prevention of future cases, but this impact will only become visible decades later, when vaccinated cohorts reach the age at which cervical cancer typically manifests.
Registry studies up to 2026 did not even prove that vaccinated and unvaccinated groups differed in recorded case counts, as those were manipulated stats. Australia’s case study demonstrates that giving undue credit to vaccines obscures the real drivers of progress. The misuse of registry data and celebratory narratives represents not isolated errors but a global and concerted effort to manipulate the scientific field.
Therefore, the correct scientific perspective is final and conclusive: cervical cancer declines were established long before vaccines, and the evidence of vaccine impact on invasive cancer will only emerge in the future. Until then, claims of vaccine‑driven declines are premature, unscientific, and reflect funding bias rather than biological reality. The field must return to honest science, acknowledging the true drivers of progress — natural immunity, screening, and healthcare — and resisting the temptation to manufacture proof where biology dictates none exists.